ANGION

Vifor Pharma and Angion report topline results from phase-II GUARD trial of ANG-3777 in cardiac surgery associated acute kidney injury

Retrieved on: 
Venerdì, Dicembre 10, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Cardiology, U.S. Securities and Exchange Commission, Renal replacement therapy, Risk, Vifor Pharma, Acute kidney injury, AKI, China, Health, Patient, Security (finance), SIX Swiss Exchange, Safety, Private Securities Litigation Reform Act, Death, LR, CKD, ISIN, Cardiopulmonary bypass, Nephrology, ART, ROCK2, CYP11B2, MD, Fresenius Medical Care, Incidence, COVID-19, Multimedia, Degenerative disease, HGF, Conditional sentence, NASDAQ, Glomerular filtration rate, Half-life, EGFR, AUC, Odds ratio, Hepatocyte growth factor, Pharmaceutical industry, Medical imaging, Vifor Pharma Group, Angion, ANG-3777, the GUARD phase-II study, VIFOR PHARMA GROUP, ANGION, ANG-3777, THE GUARD PHASE-II STUDY

53 LR

Key Points: 
  • 53 LR
    Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN) today announced results from the exploratory phase-II GUARD trial of Angions ANG-3777 in patients undergoing cardiac surgery involving cardiopulmonary bypass at risk for developing acute kidney injury (CSA-AKI).
  • However, Angion and Vifor Pharma continue to review the data, based on the signal demonstrated in the clinically-relevant MAKE90 secondary endpoint.
  • Angion and Vifor Pharma are evaluating the full data set from the Phase 2 GUARD trial in patients at risk for acute kidney injury associated with cardiac surgery involving cardiopulmonary bypass (CSA-AKI).
  • Angion and Vifor Pharma are evaluating the full data set from the phase-II GUARD trial in patients at risk for acute kidney injury associated with cardiac surgery involving cardiopulmonary bypass (CSA-AKI).

Vifor Pharma and Angion report topline results from phase-III registration trial of ANG-3777 in kidney transplant patients at risk for delayed graft function

Retrieved on: 
Mercoledì, Ottobre 27, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Surgery, Health, Clinical Trials, SIX Swiss Exchange, Nephrology, Hepatocyte growth factor, China, Vifor Pharma, Glomerular filtration rate, ISIN, Acute kidney injury, ART, HGF, Fresenius Medical Care, DGF, U.S. Securities and Exchange Commission, Patient, NASDAQ, Cardiopulmonary bypass, Private Securities Litigation Reform Act, CYP11B2, EGFR, Review, Risk, Security (finance), Kidney, Transplant, CEO, COVID-19, Multimedia, Oliguria, Conditional sentence, Half-life, CSA, ROCK2, Health, Population, LR, Pharmaceutical industry, Vifor Pharma Group, Angion, ANG-3777, VIFOR PHARMA GROUP, ANGION, ANG-3777

Based upon these data, it is not expected there is sufficient evidence to support an indication in the studied DGF population.

Key Points: 
  • Based upon these data, it is not expected there is sufficient evidence to support an indication in the studied DGF population.
  • Under this analysis, ANG-3777 showed a difference on 12 month eGFR of 57.1mL/min/1.73m2 versus 52.2mL/min/1.73m2 (4.9mL/min/1.73m2, p=0.06) for placebo.
  • Our collaboration with Angion and the development of ANG-3777 in cardiac-surgery associated acute kidney injury (CSA-AKI) continues unchanged, with topline data expected later this year.
  • Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives.

Vifor Pharma and Angion announce completion of enrollment in phase-II study of ANG-3777 for cardiac-surgery associated acute kidney injury

Retrieved on: 
Giovedì, Aprile 29, 2021
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Surgery, Health, Clinical trials, Medical specialties, Anatomy, Kidney diseases, Branches of biology, Organ failure, Acute kidney injury, Vifor Pharma, Aki, Acute respiratory distress syndrome, ANG-3777, Vifor Pharma Group, Angion, ANG-3777, VIFOR PHARMA GROUP, ANGION

View the full release here: https://www.businesswire.com/news/home/20210428005922/en/\nVifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN), today announced completion of enrollment for Angion\xe2\x80\x99s AKI-002-15 study, a phase-II trial of ANG-3777 in patients at risk of cardiac-surgery associated acute kidney injury (CSA-AKI).

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210428005922/en/\nVifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN), today announced completion of enrollment for Angion\xe2\x80\x99s AKI-002-15 study, a phase-II trial of ANG-3777 in patients at risk of cardiac-surgery associated acute kidney injury (CSA-AKI).
  • Klaus Henning Jensen, Chief Medical Officer of Vifor Pharma Group commented: \xe2\x80\x9cWe are excited that enrollment in the AKI-002-15 phase-II trial has completed.
  • The first dose was given within four hours of the completion of surgery with subsequent doses given at 24-hour intervals.
  • Enrollment is complete in a phase-III registration trial in transplant-associated acute kidney injury, also known as delayed graft function, a phase-II exploratory trial in cardiac-surgery associated acute kidney injury, and a phase-II exploratory trial in patients with acute lung injury associated with COVID-19 pneumonia.